New Paradigm in Global Drug Development
At LeaderMed, a global, innovative biopharmaceutical company, we are dedicated to leverage the Asia-Pacific market and expedite drug development cost-effectively.
Zoom webinar
Conference 2022
We are looking forward to seeing you in this exciting program.
Seats
300 People
Time
07 Sept. 2022
Speaker
6 Professional
What About Event
Examine trends impacting the global biopharmaceutical industry, including drug development timelines, cost, pricing changes, shifting regulatory environments, and the largely untapped Asia-Pacific (APAC) market. Speakers from life science industry and investment community will provide their unique insights on these topics.
Who We Are?
After you design a couple thousand screens for various products, you’ll start to see that they’re basically all the same anyway.
What We Do?
After you design a couple thousand screens for various products, you’ll start to see that they’re basically all the same anyway.
Our Goals?
After you design a couple thousand screens for various products, you’ll start to see that they’re basically all the same anyway.
Conference Speakers
Speakers will provide insights on:
- How biopharmaceutical organizations could potentially reduce the time and cost of drug development by leveraging a unique pathway directly into Phase 3 or pivotal clinical trials in China.
- Pending U.S. drug pricing regulation that is expected to drastically alter the pharmaceutical landscape, and why biotech investors must consider making APAC, the fastest-growing pharmaceutical market, an earlier and larger part of their drug development strategies.
- Why APAC represents a largely untapped market opportunity for the pharmaceutical industry, and how biopharmaceutical organizations can further penetrate this strategic market while fast-tracking clinical trials and reducing overall costs.
Founder & CEO, LeaderMed Health Group Limited (“LeaderMed Group”)
Dr. Joanne Jiang has over 20 years of executive experience in the global Pharma industry including senior leadership positions with Sanofi, Bayer, and Daiichi Sankyo, leading the company’s global new drug development teams. She led clinical development and regulatory approval of Actonel and Lantus with the US FDA, EMEA, CFDA and PMDA. As co-founder of Fountain Medical Development, she worked with over 60 global Pharma clients and obtained regulatory approval for 20+ products. Dr. Jiang serves as a director to several US and China biotechnology companies, is a distinguished scholar of the Real-World Evidence Data Institute and has published 13 international papers. She is a senior scholar of Chinese Pharma Assoc., the leading academic association that is collaborating with NMPA (Chinese FDA), responsible for scientific evaluation of new drug research in China. Dr. Jiang holds a Ph.D. in pharmacology/toxicology from Indiana School of Medical, and an MBA from University of Michigan.
Executive Deputy Director of China's Hainan Provincial Food and Drug Administration
Xiaolei Lv is currently serving as executive deputy director of China’s Hainan Provincial Food and Drug Administration (in charge of drug approval and pricing). She was the president of the Hainan Special district Red Cross Society and the director of the Health Industry and Foreign Cooperation Bureau of the Hainan Provincial Health Commission.
CEO Transition Therapeutics @OPKO Health, Inc.
Dr. Cruz is the Founder, Chairman, and CEO of Transition Therapeutics Inc, now a subsidiary of OPKO Health, which led several development programs, including an oral compound for the treatment of cognition, agitation, and aggression in Alzheimer’s disease partnered with Elan pharmaceuticals, a GLP-1 dual agonist for the treatment of type 2 diabetes partnered with Eli Lilly, and a SARM for the treatment of muscle wasting. Dr. Cruz was Co-founder of Angiotech Pharmaceuticals Inc and served as VP of R&D and member of the Board of Directors. Angiotech developed a Taxol coated stent that was partnered with Boston Scientific. Dr. Cruz founded three other small biotech companies and sold to publicly traded biotech companies. Dr. Cruz had a successful academic career with over 150 publications. He was a senior scientist at Mt. Sinai Hospital and a Prof of Lab Med at the Univ. of Toronto. Dr. Cruz was a Founder, Director, and CEO of the Canadian Arthritis Network (CAN).
Vice President, Internal Medicine, ICON plc.
Over 20 years’ experience in the Pharma industry, clinical research, across all phases of product development, providing therapeutic area specific consulting and drug development expertise to ICON’s pharmaceutical/biotech clients, assisting them in successful development and delivery of drug portfolio. Strategic resource in leading medical/scientific project development and horizon pipeline architecture for client companies and across Internal Medicine therapeutic area with focus on Vaccine, Cardiometabolic, and Women’s Health indications in collaboration with ICON management. Projects include novel insulin delivery systems, inhaled rapid acting insulins, novel mechanisms for metabolic disease including Obesity and NASH/NAFLD. Facilitated support with a network of former FDA and Biotech/Pharma specialists for Pharma companies across all phases of product development.
Director of Project Management, Clinical CRO Division, CMIC Group
Takashi is the Director of International Clinical Development in CMIC. After receiving his master’s degree in Pharmacy, Takashi started out his career as a researcher at a pharma company. He has experience of over 15 years in oncology field, handling approximately 15 studies as Clinical Research Associate, Project Leader, and Project Manager for both global and local studies. He is capable of providing various services such as strategic development planning, clinical operation, and project management including interaction with regulatory agency and KOLs. Takashi has earned strong trust from his customers with his broad experience and capability.